Abstract
The effect of long-term antiretroviral therapy on serum immune activation markers was assessed in a cohort of 63 patients before and after 6 years of boosted lopinavir - based antiretroviral therapy. High levels of most markers were associated with lower CD4+ T cell counts at baseline and at year 6, with the exception of soluble cytotoxic T lymphocyte antigen-4 (sCTLA-4); high levels of sCTLA-4 were associated with higher CD4+ T cell counts at year 6. Abnormalities of serum immune activation markers persisted after 6 years of ART but probably had different causes. Further investigation of the clinical usefulness of assaying immunoglobulin A, neopterin, and sCTLA-4 levels to assess the effectiveness of treatments for human immunodeficiency virus (HIV) disease are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 1212-1215 |
Number of pages | 4 |
Journal | Journal of Infectious Diseases |
Volume | 200 |
Issue number | 8 |
DOIs | |
State | Published - Oct 15 2009 |
Externally published | Yes |
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases